<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01191268</url>
  </required_header>
  <id_info>
    <org_study_id>11376</org_study_id>
    <secondary_id>H9X-MC-GBDD</secondary_id>
    <nct_id>NCT01191268</nct_id>
  </id_info>
  <brief_title>A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)</brief_title>
  <official_title>The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of LY2189265 in comparison to
      Insulin Glargine, both in combination with Insulin Lispro (plus or minus Metformin), in
      participants with Type 2 Diabetes treated with 1 or 2 injections of insulin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The term rescue therapy in this trial was defined as therapy for participants who met
      criteria for persistent severe hyperglycemia and therapy for participants who required new
      intervention for any other reason. The latter included participants who discontinued study
      drug due to adverse events, participant decision, or any other reason. For efficacy analyses,
      participants who received rescue medication were included in the analysis population, but
      only measurements obtained prior to taking rescue therapy were included in the efficacy
      analysis. For safety analyses, with the exception of hypoglycemia, all measurements including
      those obtained after taking rescue therapy were included in the analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)</measure>
    <time_frame>Baseline, 26 weeks</time_frame>
    <description>Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, baseline metformin, and baseline HbA1c.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 52-week Endpoint in Glycosylated Hemoglobin (HbA1c)</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, baseline metformin, and baseline HbA1c.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at Weeks 26 and 52</measure>
    <time_frame>26 weeks and 52 weeks</time_frame>
    <description>The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a repeated logistic regression model (generalized estimating equation model) with baseline HbA1c, baseline metformin, country, and treatment as factors included in the model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 26 and 52 Weeks in the Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than 7% Without Nocturnal or Severe Hypoglycemia</measure>
    <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
    <description>The percentage of participants achieving HbA1c less than 7.0% without nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking) or severe (episodes requiring the assistance of another person to actively administer resuscitative actions) hypoglycemia was analyzed with a repeated logistic regression model (generalized estimating equation model) with baseline HbA1c, baseline metformin, country, and treatment as factors included in the model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 26 and 52 Weeks in Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles</measure>
    <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
    <description>The self-monitored plasma glucose (SMPG) data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. The mean of the 8 time points (Daily Mean) was also calculated. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, metformin, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 26 and 52 Weeks in Fasting Serum Glucose</measure>
    <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
    <description>Fasting serum glucose was measured by the central laboratory. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline fasting blood glucose as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Insulin Dose Overall and by Components (Insulin Lispro and Insulin Glargine)</measure>
    <time_frame>Baseline and 26 weeks and 52 weeks</time_frame>
    <description>Total daily insulin (TDI) dose was reported at baseline, 26 weeks, and 52 weeks. Daily Insulin Lispro and Insulin Glargine doses were reported at 26 and 52 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 26 and 52 Weeks in Body Weight</measure>
    <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
    <description>Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline body weight as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight at Baseline, 52 Weeks, and 4 Weeks After Last Dose</measure>
    <time_frame>Baseline and 52 weeks and 4 weeks after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose in Body Mass Index (BMI)</measure>
    <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
    <description>Body mass index is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline BMI as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 26 and 52 Weeks in the EQ-5D</measure>
    <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
    <description>The EQ-5D questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part consists of a visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, metformin use, and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Activities of Daily Living (IW-ADL)</measure>
    <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
    <description>The Impact of Weight on Activities of Daily Living questionnaire (renamed the Ability to Perform Physical Activities of Daily Living Questionnaire [APPADL]) contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = &quot;not at all difficult&quot; and 1 = &quot;unable to do&quot;. The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline score as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Self-Perception (IW-SP)</measure>
    <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
    <description>The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline score as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 26 and 52 Weeks in the Low Blood Sugar Survey (LBSS)</measure>
    <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
    <description>The Low Blood Sugar Survey (LBSS) contains 33 items comprised of 2 subscales (behavior and worry), each of which is rated on a 5-point numeric rating scale from 0 (never) to 4 (almost always). It captures behavioral changes associated with the concerns and experiences of hypoglycemia and the degree to which participants are worried about certain aspects associated with hypoglycemia during the previous 4 weeks. The behavior (or avoidance) subscale has 15 items, and the worry (or affect) subscale has 18 items. Subscale scores are calculated by summing participant responses to items (behavior range 0-60; worry range 0-72). A total score is calculated as the sum of both subscales (range 0-132). Higher scores indicate greater negative impact on subscales and total score. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment and metformin use as fixed effects and baseline score as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 26 and 52 Weeks in Pancreatic Enzymes</measure>
    <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
    <description>Amylase (total and pancreas-derived [PD]) and lipase concentrations were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pancreatic Enzymes at Baseline, 52 Weeks, and 4 Weeks After Last Dose</measure>
    <time_frame>Baseline and 52 weeks and 4 weeks after last dose</time_frame>
    <description>Amylase (total and pancreas-derived [PD]) and lipase concentrations were measured at baseline and at 4 weeks after last dose (ALD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 26 and 52 Weeks in Serum Calcitonin</measure>
    <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Calcitonin at Baseline, 52 Weeks, and 4 Weeks After Last Dose</measure>
    <time_frame>Baseline and 52 weeks and 4 weeks after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 26 and 52 Weeks in Blood Pressure</measure>
    <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
    <description>Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline blood pressure as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure at Baseline, 52 Weeks, and 4 Weeks After Last Dose</measure>
    <time_frame>Baseline and 52 weeks and 4 weeks after last dose</time_frame>
    <description>Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 26 and 52 Weeks in Pulse Rate</measure>
    <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
    <description>Seated pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline as a covariate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Rate at Baseline, 52 Weeks, and 4 Weeks After Last Dose</measure>
    <time_frame>Baseline and 52 weeks and 4 weeks after last dose</time_frame>
    <description>Seated pulse rate was measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval</measure>
    <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
    <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline value as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Heart Rate</measure>
    <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
    <description>Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline value as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events of Adjudicated Pancreatitis up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>The number of adjudicated (by an independent Clinical Endpoint Committee [CEC]) pancreatic events is summarized at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Self-reported Hypoglycemic Events up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose</measure>
    <time_frame>Baseline through 26 weeks and 52 weeks</time_frame>
    <description>Hypoglycemic events (HE) were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions and had a plasma glucose [PG] of ≤ 70 milligrams per deciliter [mg/dL]), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a PG of ≤ 70 mg/dL), or asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL). The number of participants with self-reported hypoglycemic events is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Self-reported Hypoglycemic Events up to 52 Weeks</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>Hypoglycemic events (HE) were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions and had a plasma glucose [PG] of ≤ 70 milligrams per deciliter [mg/dL]), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a PG of ≤ 70 mg/dL), or asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adjudicated Cardiovascular Events up to 52 Weeks</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent LY2189265 Antibodies up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose</measure>
    <time_frame>Baseline through 4 weeks after last dose</time_frame>
    <description>A participant was considered to have treatment emergent LY2189265 anti-drug antibodies (ADA) if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose</measure>
    <time_frame>Baseline through 26 weeks, 52 weeks, and 4 weeks after last dose</time_frame>
    <description>A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 weeks, 52 weeks, and 4 weeks after last dose. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">884</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>1.5 mg LY2189265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.75 mg LY2189265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <arm_group_label>Insulin Glargine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2189265</intervention_name>
    <arm_group_label>1.5 mg LY2189265</arm_group_label>
    <arm_group_label>0.75 mg LY2189265</arm_group_label>
    <other_name>Dulaglutide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <arm_group_label>1.5 mg LY2189265</arm_group_label>
    <arm_group_label>0.75 mg LY2189265</arm_group_label>
    <arm_group_label>Insulin Glargine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  Currently using insulin for at least 3 months with a conventional insulin regimen with
             or without oral medications

          -  Glycosylated hemoglobin (HbA1c) greater than or equal to 7% and less than or equal to
             11%

          -  Willing to inject subcutaneous medication

          -  Willing to monitor blood glucose levels and adjust insulin dose

          -  Willing to maintain a study diary

          -  Body mass index (BMI) between 23 and 45 kilograms per square meter (kg/m^2)

          -  Stable weight for 3 months prior to screening

          -  Females of child bearing potential must test negative for pregnancy at screening and
             be willing to use a reliable method of birth control during the study and for 1 month
             following the last dose of study drug

        Exclusion Criteria:

          -  Type 1 Diabetes

          -  Previous therapy with glucagon-like peptide 1 (GLP-1) agonists within 3 months prior
             to screening

          -  1 or more episodes of ketoacidosis within 6 months prior to screening

          -  Have been treated with prescription or over the counter medication to promote weight
             loss within 3 months prior to screening

          -  Estimated glomerular filtration rate (eGFR) less than or equal to 30 milliliters per
             minute per 1.73 square meters (mL/min/1.73 m^2) at screening

          -  Taking steroids for greater than 14 days except for topical, eye, nasal, or inhaled

          -  History of heart failure, New York Heart Classification III or IV within 2 months
             prior to screening

          -  Gastrointestinal (GI) problems such as diabetic gastroparesis or bariatric surgery
             (stomach stapling) or chronically taking medications that directly affect GI motility

          -  Acute or chronic hepatitis or pancreatitis

          -  Self or family history of 2A or type 2B multiple endocrine neoplasia or medullary
             C-Cell hyperplasia

          -  Serum calcitonin greater than or equal to 20 picograms per milliliter (pcg/mL) at
             screening

          -  Organ transplant except cornea

          -  Significant active autoimmune disease such as Lupus or Rheumatoid Arthritis

          -  History of or active malignancy except skin or in situ cervical or prostate cancer
             within the last 5 years

          -  Known drug or alcohol abuse

          -  Have enrolled in another clinical trial within the last 30 days

          -  Have previously signed an informed consent or participated in a LY2189265 study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <zip>01830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <zip>03063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <zip>98003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1034ACO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cipolletti</city>
        <zip>8324</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500CCE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salta</city>
        <zip>4406</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Keswick</city>
        <state>South Australia</state>
        <zip>5035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Belem</city>
        <zip>66073-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fortaleza</city>
        <zip>60430-350</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-170</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>São Paulo</city>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 3W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6G 4X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8V 2P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1G 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hillerod</city>
        <zip>Dk-3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kobenhavn</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Koege</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kolding</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ampelokipoi</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nikaias - Piraeus</city>
        <zip>18454</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54639</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bekescsaba</city>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Budapest</city>
        <zip>1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gyongyos</city>
        <zip>3200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nagykanizsa</city>
        <zip>8800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Papa</city>
        <zip>8500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Culiacan</city>
        <zip>80020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guadalajara</city>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Merida</city>
        <zip>97070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monterrey</city>
        <zip>64461</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gdynia</city>
        <zip>81-557</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lodz</city>
        <zip>90-242</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Radzymin</city>
        <zip>05-250</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-349</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Manati</city>
        <zip>00674</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ponce</city>
        <zip>00728</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <zip>00917-3104</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yabucoa</city>
        <zip>00767</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Moscow</city>
        <zip>127486</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palma De Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pozuelo De Alarcon</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Teruel</city>
        <zip>44002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Karlstad</city>
        <zip>65185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stockholm</city>
        <zip>113 61</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sindian City</city>
        <zip>23148</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taipei</city>
        <zip>11031</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yong Kang City</city>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>South Africa</country>
  </removed_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2010</study_first_submitted>
  <study_first_submitted_qc>August 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2010</study_first_posted>
  <results_first_submitted>October 3, 2014</results_first_submitted>
  <results_first_submitted_qc>October 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 8, 2014</results_first_posted>
  <disposition_first_submitted>May 24, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 24, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 1, 2012</disposition_first_posted>
  <last_update_submitted>October 3, 2014</last_update_submitted>
  <last_update_submitted_qc>October 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Dulaglutide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1.5 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
        </group>
        <group group_id="P2">
          <title>0.75 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
        </group>
        <group group_id="P3">
          <title>Insulin Glargine</title>
          <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="295"/>
                <participants group_id="P2" count="293"/>
                <participants group_id="P3" count="296"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="295"/>
                <participants group_id="P2" count="293"/>
                <participants group_id="P3" count="296"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="237"/>
                <participants group_id="P2" count="238"/>
                <participants group_id="P3" count="244"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who were randomized and received at least 1 dose of LY2189265 or Insulin Glargine.</population>
      <group_list>
        <group group_id="B1">
          <title>1.5 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
        </group>
        <group group_id="B2">
          <title>0.75 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
        </group>
        <group group_id="B3">
          <title>Insulin Glargine</title>
          <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="295"/>
            <count group_id="B2" value="293"/>
            <count group_id="B3" value="296"/>
            <count group_id="B4" value="884"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.88" spread="9.55"/>
                    <measurement group_id="B2" value="59.31" spread="8.98"/>
                    <measurement group_id="B3" value="59.90" spread="9.08"/>
                    <measurement group_id="B4" value="59.36" spread="9.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="131"/>
                    <measurement group_id="B4" value="411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="165"/>
                    <measurement group_id="B4" value="473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="193"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="196"/>
                    <measurement group_id="B4" value="581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="231"/>
                    <measurement group_id="B4" value="697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.00" spread="18.24"/>
                    <measurement group_id="B2" value="91.69" spread="18.03"/>
                    <measurement group_id="B3" value="90.75" spread="18.87"/>
                    <measurement group_id="B4" value="91.14" spread="18.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Body mass index is an estimate of body fat based on body weight divided by height squared.</description>
          <units>kilograms per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.99" spread="5.11"/>
                    <measurement group_id="B2" value="33.08" spread="5.15"/>
                    <measurement group_id="B3" value="32.41" spread="5.33"/>
                    <measurement group_id="B4" value="32.49" spread="5.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Hemoglobin (HbA1c)</title>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.46" spread="1.08"/>
                    <measurement group_id="B2" value="8.40" spread="1.03"/>
                    <measurement group_id="B3" value="8.53" spread="1.03"/>
                    <measurement group_id="B4" value="8.46" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.80" spread="7.19"/>
                    <measurement group_id="B2" value="12.43" spread="6.92"/>
                    <measurement group_id="B3" value="12.96" spread="6.80"/>
                    <measurement group_id="B4" value="12.73" spread="6.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)</title>
        <description>Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, baseline metformin, and baseline HbA1c.</description>
        <time_frame>Baseline, 26 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable HbA1c data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)</title>
          <description>Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, baseline metformin, and baseline HbA1c.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable HbA1c data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="275"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.64" spread="0.07"/>
                    <measurement group_id="O2" value="-1.59" spread="0.07"/>
                    <measurement group_id="O3" value="-1.41" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The study was designed to enroll 837 randomized participants (279 per treatment arm) with 90% power to detect non-inferiority of 1.5 mg LY2189265 versus Insulin Glargine on HbA1c change from baseline at the 26-week primary endpoint with a margin of 0.4%, a standard deviation of 1.3%, and a 1-sided alpha of 0.025 assuming no true difference between treatments. This corresponds to 248 participants per arm, with an assumed drop-out rate of 11%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the upper limit of the 95% Confidence Interval (CI) of 1.5 mg LY2189265 versus Insulin Glargine was below 0.4%, 1.5 mg LY2189265 was declared non-inferior to Insulin Glargine.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Family-wise Type I error rate was controlled by applying tree-gatekeeping strategy.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 1-sided adjusted p-value was below 0.025, then 0.75 mg LY2189265 was declared non-inferior to Insulin Glargine.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Family-wise Type I error rate was controlled by applying tree-gatekeeping strategy.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Superiority analysis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>Family-wise Type I error rate was controlled by applying tree-gatekeeping strategy.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Superiority analysis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <p_value_desc>Family-wise Type I error rate was controlled by applying tree-gatekeeping strategy.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 52-week Endpoint in Glycosylated Hemoglobin (HbA1c)</title>
        <description>Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, baseline metformin, and baseline HbA1c.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable HbA1c data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 52-week Endpoint in Glycosylated Hemoglobin (HbA1c)</title>
          <description>Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, baseline metformin, and baseline HbA1c.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable HbA1c data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="275"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="0.08"/>
                    <measurement group_id="O2" value="-1.42" spread="0.08"/>
                    <measurement group_id="O3" value="-1.23" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the upper limit of the 95% Confidence Interval (CI) of 1.5 mg LY2189265 versus Insulin Glargine was below 0.4%, 1.5 mg LY2189265 was declared non-inferior to Insulin Glargine.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Family-wise Type I error rate was controlled by applying tree-gatekeeping strategy.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 1-sided adjusted p-value was below 0.025, then 0.75 mg LY2189265 was declared non-inferior to Insulin Glargine.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Family-wise Type I error rate was controlled by applying tree-gatekeeping strategy.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Superiority analysis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>Family-wise Type I error rate was controlled by applying tree-gatekeeping strategy.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Superiority analysis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>Family-wise Type I error rate was controlled by applying tree-gatekeeping strategy.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at Weeks 26 and 52</title>
        <description>The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a repeated logistic regression model (generalized estimating equation model) with baseline HbA1c, baseline metformin, country, and treatment as factors included in the model.</description>
        <time_frame>26 weeks and 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable HbA1c data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at Weeks 26 and 52</title>
          <description>The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a repeated logistic regression model (generalized estimating equation model) with baseline HbA1c, baseline metformin, country, and treatment as factors included in the model.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable HbA1c data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="277"/>
                <count group_id="O3" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HbA1c less than 7.0%, 26 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.6"/>
                    <measurement group_id="O2" value="69.0"/>
                    <measurement group_id="O3" value="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c less than 7.0%, 52 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5"/>
                    <measurement group_id="O2" value="56.3"/>
                    <measurement group_id="O3" value="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c less than or equal to 6.5%, 26 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0"/>
                    <measurement group_id="O2" value="43.0"/>
                    <measurement group_id="O3" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c less than or equal to 6.5%, 52 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7"/>
                    <measurement group_id="O2" value="34.7"/>
                    <measurement group_id="O3" value="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>Treatment comparison for HbA1c less than 7.0% at 26 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>Treatment comparison for HbA1c less than 7.0% at 26 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <p_value_desc>Treatment comparison for HbA1c less than or equal to 6.5% at 26 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.384</p_value>
            <p_value_desc>Treatment comparison for HbA1c less than or equal to 6.5% at 26 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Treatment comparison for HbA1c less than 7% at 52 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.250</p_value>
            <p_value_desc>Treatment comparison for HbA1c less than 7% at 52 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.272</p_value>
            <p_value_desc>Treatment comparison for HbA1c less than or equal to 6.5% at 52 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.623</p_value>
            <p_value_desc>Treatment comparison for HbA1c less than or equal to 6.5% at 52 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 26 and 52 Weeks in the Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than 7% Without Nocturnal or Severe Hypoglycemia</title>
        <description>The percentage of participants achieving HbA1c less than 7.0% without nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking) or severe (episodes requiring the assistance of another person to actively administer resuscitative actions) hypoglycemia was analyzed with a repeated logistic regression model (generalized estimating equation model) with baseline HbA1c, baseline metformin, country, and treatment as factors included in the model.</description>
        <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 26 and 52 Weeks in the Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than 7% Without Nocturnal or Severe Hypoglycemia</title>
          <description>The percentage of participants achieving HbA1c less than 7.0% without nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking) or severe (episodes requiring the assistance of another person to actively administer resuscitative actions) hypoglycemia was analyzed with a repeated logistic regression model (generalized estimating equation model) with baseline HbA1c, baseline metformin, country, and treatment as factors included in the model.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="277"/>
                <count group_id="O3" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8"/>
                    <measurement group_id="O2" value="54.5"/>
                    <measurement group_id="O3" value="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0"/>
                    <measurement group_id="O2" value="44.0"/>
                    <measurement group_id="O3" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 26 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 26 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 52 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 52 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 26 and 52 Weeks in Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles</title>
        <description>The self-monitored plasma glucose (SMPG) data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. The mean of the 8 time points (Daily Mean) was also calculated. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, metformin, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
        <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable SMPG data. Only pre-rescue measurements were used.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 26 and 52 Weeks in Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles</title>
          <description>The self-monitored plasma glucose (SMPG) data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. The mean of the 8 time points (Daily Mean) was also calculated. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, metformin, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable SMPG data. Only pre-rescue measurements were used.</population>
          <units>millimoles per liter (mmol/L)]</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-morning meal, 26 weeks (n=228, 231, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.14"/>
                    <measurement group_id="O2" value="-0.06" spread="0.14"/>
                    <measurement group_id="O3" value="-2.01" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-morning meal, 26 weeks (n=220, 227, 229)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.70" spread="0.19"/>
                    <measurement group_id="O2" value="-3.29" spread="0.19"/>
                    <measurement group_id="O3" value="-4.03" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-midday meal, 26 weeks (n=227, 231, 233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.80" spread="0.16"/>
                    <measurement group_id="O2" value="-2.38" spread="0.16"/>
                    <measurement group_id="O3" value="-2.65" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-midday meal, 26 weeks (n=219, 227, 228)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.51" spread="0.17"/>
                    <measurement group_id="O2" value="-4.53" spread="0.17"/>
                    <measurement group_id="O3" value="-3.70" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-evening meal, 26 weeks (n=226, 231, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.24" spread="0.16"/>
                    <measurement group_id="O2" value="-3.06" spread="0.16"/>
                    <measurement group_id="O3" value="-2.74" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-evening meal, 26 weeks (n=220, 228, 227)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.61" spread="0.17"/>
                    <measurement group_id="O2" value="-4.54" spread="0.17"/>
                    <measurement group_id="O3" value="-3.90" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bedtime, 26 weeks (n=220, 221, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.00" spread="0.17"/>
                    <measurement group_id="O2" value="-3.89" spread="0.17"/>
                    <measurement group_id="O3" value="-3.40" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After bedtime, 26 weeks (n=208, 216, 208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="0.15"/>
                    <measurement group_id="O2" value="-1.50" spread="0.15"/>
                    <measurement group_id="O3" value="-1.96" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily Mean, 26 weeks (n=202, 206, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.17" spread="0.12"/>
                    <measurement group_id="O2" value="-2.97" spread="0.12"/>
                    <measurement group_id="O3" value="-3.10" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-morning meal, 52 weeks (n=207, 213, 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.16"/>
                    <measurement group_id="O2" value="0.05" spread="0.15"/>
                    <measurement group_id="O3" value="-2.02" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-morning meal, 52 weeks (n=200, 211, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.38" spread="0.19"/>
                    <measurement group_id="O2" value="-3.23" spread="0.19"/>
                    <measurement group_id="O3" value="-3.76" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-midday meal, 52 weeks (n=207, 213, 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.53" spread="0.14"/>
                    <measurement group_id="O2" value="-2.52" spread="0.14"/>
                    <measurement group_id="O3" value="-2.63" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-midday meal, 52 weeks (n=202, 210, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.33" spread="0.18"/>
                    <measurement group_id="O2" value="-4.29" spread="0.18"/>
                    <measurement group_id="O3" value="-3.83" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-evening meal, 52 weeks (n=207, 214, 217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="0.16"/>
                    <measurement group_id="O2" value="-3.07" spread="0.16"/>
                    <measurement group_id="O3" value="-2.67" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-evening meal, 52 weeks (n=200, 210, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.22" spread="0.17"/>
                    <measurement group_id="O2" value="-4.54" spread="0.17"/>
                    <measurement group_id="O3" value="-3.71" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bedtime, 52 weeks (n=195, 205, 213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.62" spread="0.17"/>
                    <measurement group_id="O2" value="-3.96" spread="0.17"/>
                    <measurement group_id="O3" value="-3.27" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After bedtime, 52 weeks (n=192, 192 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="0.15"/>
                    <measurement group_id="O2" value="-1.36" spread="0.15"/>
                    <measurement group_id="O3" value="-1.80" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily Mean, 52 weeks (n=182, 185, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.84" spread="0.12"/>
                    <measurement group_id="O2" value="-2.95" spread="0.12"/>
                    <measurement group_id="O3" value="-2.97" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.628</p_value>
            <p_value_desc>Treatment comparison of Daily Mean values at 26 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.368</p_value>
            <p_value_desc>Treatment comparison of Daily Mean values at 26 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.370</p_value>
            <p_value_desc>Treatment comparison of Daily Mean values at 52 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.879</p_value>
            <p_value_desc>Treatment comparison of Daily Mean values at 52 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 26 and 52 Weeks in Fasting Serum Glucose</title>
        <description>Fasting serum glucose was measured by the central laboratory. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline fasting blood glucose as a covariate.</description>
        <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable fasting blood glucose data. Only pre-rescue measurements were used.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 26 and 52 Weeks in Fasting Serum Glucose</title>
          <description>Fasting serum glucose was measured by the central laboratory. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline fasting blood glucose as a covariate.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable fasting blood glucose data. Only pre-rescue measurements were used.</population>
          <units>millimoles per liter (mmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="292"/>
                <count group_id="O3" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 weeks (n=253, 256, 255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.20"/>
                    <measurement group_id="O2" value="0.22" spread="0.20"/>
                    <measurement group_id="O3" value="-1.58" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks (n=237, 238, 246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.22"/>
                    <measurement group_id="O2" value="0.41" spread="0.22"/>
                    <measurement group_id="O3" value="-1.01" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 26 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 26 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.32</ci_lower_limit>
            <ci_upper_limit>2.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 52 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 52 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Insulin Dose Overall and by Components (Insulin Lispro and Insulin Glargine)</title>
        <description>Total daily insulin (TDI) dose was reported at baseline, 26 weeks, and 52 weeks. Daily Insulin Lispro and Insulin Glargine doses were reported at 26 and 52 weeks.</description>
        <time_frame>Baseline and 26 weeks and 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Insulin Dose Overall and by Components (Insulin Lispro and Insulin Glargine)</title>
          <description>Total daily insulin (TDI) dose was reported at baseline, 26 weeks, and 52 weeks. Daily Insulin Lispro and Insulin Glargine doses were reported at 26 and 52 weeks.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine.</population>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TDI, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.20" spread="32.17"/>
                    <measurement group_id="O2" value="59.11" spread="38.12"/>
                    <measurement group_id="O3" value="53.93" spread="30.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TDI, 26 weeks (n=244, 251, 254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.24" spread="78.02"/>
                    <measurement group_id="O2" value="96.69" spread="62.13"/>
                    <measurement group_id="O3" value="132.00" spread="79.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TDI, 52 weeks (n=224, 227, 238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.15" spread="62.95"/>
                    <measurement group_id="O2" value="95.00" spread="67.62"/>
                    <measurement group_id="O3" value="133.19" spread="80.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insulin Lispro, 26 weeks (n=244, 251, 254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.24" spread="78.02"/>
                    <measurement group_id="O2" value="96.69" spread="62.13"/>
                    <measurement group_id="O3" value="67.79" spread="44.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insulin Lispro, 52 weeks (n=224, 227, 238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.15" spread="62.95"/>
                    <measurement group_id="O2" value="95.00" spread="67.62"/>
                    <measurement group_id="O3" value="69.12" spread="49.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insulin Glargine, 26 weeks (n=244, 251, 254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants in this treatment arm were not exposed to Insulin Glargine.</measurement>
                    <measurement group_id="O2" value="NA">Participants in this treatment arm were not exposed to Insulin Glargine.</measurement>
                    <measurement group_id="O3" value="64.48" spread="40.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insulin Glargine, 52 weeks (n=224, 227, 238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants in this treatment arm were not exposed to Insulin Glargine.</measurement>
                    <measurement group_id="O2" value="NA">Participants in this treatment arm were not exposed to Insulin Glargine.</measurement>
                    <measurement group_id="O3" value="64.07" spread="38.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 26 and 52 Weeks in Body Weight</title>
        <description>Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline body weight as a covariate.</description>
        <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable body weight data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 26 and 52 Weeks in Body Weight</title>
          <description>Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline body weight as a covariate.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable body weight data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>kilograms (kg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="289"/>
                <count group_id="O3" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.87" spread="0.27"/>
                    <measurement group_id="O2" value="0.18" spread="0.27"/>
                    <measurement group_id="O3" value="2.33" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.34"/>
                    <measurement group_id="O2" value="0.86" spread="0.33"/>
                    <measurement group_id="O3" value="2.89" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 26 weeks.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.81</ci_lower_limit>
            <ci_upper_limit>-2.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 26 weeks.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.76</ci_lower_limit>
            <ci_upper_limit>-1.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 52 weeks.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.99</ci_lower_limit>
            <ci_upper_limit>-2.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 52 weeks.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.78</ci_lower_limit>
            <ci_upper_limit>-1.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight at Baseline, 52 Weeks, and 4 Weeks After Last Dose</title>
        <time_frame>Baseline and 52 weeks and 4 weeks after last dose</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable body weight data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight at Baseline, 52 Weeks, and 4 Weeks After Last Dose</title>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable body weight data.</population>
          <units>kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.00" spread="18.24"/>
                    <measurement group_id="O2" value="91.69" spread="18.03"/>
                    <measurement group_id="O3" value="90.75" spread="18.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks (n=290, 290, 295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.58" spread="19.06"/>
                    <measurement group_id="O2" value="93.21" spread="19.23"/>
                    <measurement group_id="O3" value="94.14" spread="19.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks after last dose (n=259, 260, 253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.69" spread="18.60"/>
                    <measurement group_id="O2" value="93.14" spread="19.20"/>
                    <measurement group_id="O3" value="94.27" spread="20.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose in Body Mass Index (BMI)</title>
        <description>Body mass index is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline BMI as a covariate.</description>
        <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable BMI data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose in Body Mass Index (BMI)</title>
          <description>Body mass index is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline BMI as a covariate.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable BMI data.</population>
          <units>kilograms per meter squared (kg/m^2)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 weeks (n=248, 251, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.09"/>
                    <measurement group_id="O2" value="0.21" spread="0.09"/>
                    <measurement group_id="O3" value="1.01" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks (n=225, 224, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.11"/>
                    <measurement group_id="O2" value="0.57" spread="0.11"/>
                    <measurement group_id="O3" value="1.33" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks after last dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data from 4 weeks after last dose was not analyzed for this outcome.</measurement>
                    <measurement group_id="O2" value="NA">Data from 4 weeks after last dose was not analyzed for this outcome.</measurement>
                    <measurement group_id="O3" value="NA">Data from 4 weeks after last dose was not analyzed for this outcome.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 26 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.44</ci_lower_limit>
            <ci_upper_limit>-0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 26 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>-0.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 52 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.55</ci_lower_limit>
            <ci_upper_limit>-0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment comparison at 52 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.06</ci_lower_limit>
            <ci_upper_limit>-0.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 26 and 52 Weeks in the EQ-5D</title>
        <description>The EQ-5D questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part consists of a visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, metformin use, and baseline.</description>
        <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable EQ-5D data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 26 and 52 Weeks in the EQ-5D</title>
          <description>The EQ-5D questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part consists of a visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, metformin use, and baseline.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable EQ-5D data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EQ-5D UK, 26 weeks (n=272, 271, 274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.01"/>
                    <measurement group_id="O2" value="-0.03" spread="0.01"/>
                    <measurement group_id="O3" value="-0.03" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ-5D UK, 52 weeks (n=274, 274, 281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.01"/>
                    <measurement group_id="O2" value="-0.04" spread="0.01"/>
                    <measurement group_id="O3" value="-0.03" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS, 26 weeks (n=278, 275, 275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.69" spread="1.00"/>
                    <measurement group_id="O2" value="-2.30" spread="1.00"/>
                    <measurement group_id="O3" value="-0.60" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS, 52 weeks (n=279, 278, 282)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="1.01"/>
                    <measurement group_id="O2" value="-2.54" spread="1.02"/>
                    <measurement group_id="O3" value="-0.18" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Activities of Daily Living (IW-ADL)</title>
        <description>The Impact of Weight on Activities of Daily Living questionnaire (renamed the Ability to Perform Physical Activities of Daily Living Questionnaire [APPADL]) contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = &quot;not at all difficult&quot; and 1 = &quot;unable to do&quot;. The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline score as a covariate.</description>
        <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable APPADL data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Activities of Daily Living (IW-ADL)</title>
          <description>The Impact of Weight on Activities of Daily Living questionnaire (renamed the Ability to Perform Physical Activities of Daily Living Questionnaire [APPADL]) contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = &quot;not at all difficult&quot; and 1 = &quot;unable to do&quot;. The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline score as a covariate.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable APPADL data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="290"/>
                <count group_id="O3" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 weeks (n=274, 270, 270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.30"/>
                    <measurement group_id="O2" value="-0.60" spread="0.31"/>
                    <measurement group_id="O3" value="-0.93" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks (n=277, 275, 279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.33"/>
                    <measurement group_id="O2" value="-1.05" spread="0.33"/>
                    <measurement group_id="O3" value="-1.28" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Self-Perception (IW-SP)</title>
        <description>The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline score as a covariate.</description>
        <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable IW-SP data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Self-Perception (IW-SP)</title>
          <description>The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline score as a covariate.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable IW-SP data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 weeks (n=277, 274, 274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.17"/>
                    <measurement group_id="O2" value="0.34" spread="0.17"/>
                    <measurement group_id="O3" value="0.18" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks (n=278, 277, 281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="0.16"/>
                    <measurement group_id="O2" value="0.22" spread="0.16"/>
                    <measurement group_id="O3" value="0.06" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 26 and 52 Weeks in the Low Blood Sugar Survey (LBSS)</title>
        <description>The Low Blood Sugar Survey (LBSS) contains 33 items comprised of 2 subscales (behavior and worry), each of which is rated on a 5-point numeric rating scale from 0 (never) to 4 (almost always). It captures behavioral changes associated with the concerns and experiences of hypoglycemia and the degree to which participants are worried about certain aspects associated with hypoglycemia during the previous 4 weeks. The behavior (or avoidance) subscale has 15 items, and the worry (or affect) subscale has 18 items. Subscale scores are calculated by summing participant responses to items (behavior range 0-60; worry range 0-72). A total score is calculated as the sum of both subscales (range 0-132). Higher scores indicate greater negative impact on subscales and total score. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment and metformin use as fixed effects and baseline score as a covariate.</description>
        <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable LBSS data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 26 and 52 Weeks in the Low Blood Sugar Survey (LBSS)</title>
          <description>The Low Blood Sugar Survey (LBSS) contains 33 items comprised of 2 subscales (behavior and worry), each of which is rated on a 5-point numeric rating scale from 0 (never) to 4 (almost always). It captures behavioral changes associated with the concerns and experiences of hypoglycemia and the degree to which participants are worried about certain aspects associated with hypoglycemia during the previous 4 weeks. The behavior (or avoidance) subscale has 15 items, and the worry (or affect) subscale has 18 items. Subscale scores are calculated by summing participant responses to items (behavior range 0-60; worry range 0-72). A total score is calculated as the sum of both subscales (range 0-132). Higher scores indicate greater negative impact on subscales and total score. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment and metformin use as fixed effects and baseline score as a covariate.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable LBSS data. Only pre-rescue measurements were used. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="292"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 weeks (n=251, 256, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" spread="1.31"/>
                    <measurement group_id="O2" value="2.91" spread="1.29"/>
                    <measurement group_id="O3" value="2.83" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks (n=234, 238, 244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.51" spread="1.25"/>
                    <measurement group_id="O2" value="0.92" spread="1.23"/>
                    <measurement group_id="O3" value="2.38" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 26 and 52 Weeks in Pancreatic Enzymes</title>
        <description>Amylase (total and pancreas-derived [PD]) and lipase concentrations were measured.</description>
        <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable pancreatic enzyme data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 26 and 52 Weeks in Pancreatic Enzymes</title>
          <description>Amylase (total and pancreas-derived [PD]) and lipase concentrations were measured.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable pancreatic enzyme data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>units per liter (U/L)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Amylase (total), 26 weeks (n=284, 282, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="-2.00" upper_limit="15.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="-1.00" upper_limit="10.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="-4.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase (total), 52 weeks (n=284, 283, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="-3.00" upper_limit="12.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="-4.00" upper_limit="9.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-7.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase (PD), 26 weeks (n=284, 282, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="0.00" upper_limit="10.00"/>
                    <measurement group_id="O2" value="2.50" lower_limit="0.00" upper_limit="7.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="-2.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase (PD), 52 weeks (n=284, 283, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="-2.00" upper_limit="9.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="-2.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-3.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase, 26 weeks (n=284, 282, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.00" lower_limit="0.00" upper_limit="17.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="-3.00" upper_limit="12.00"/>
                    <measurement group_id="O3" value="-2.00" lower_limit="-8.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase, 52 weeks (n=284, 283, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="-1.00" upper_limit="16.50"/>
                    <measurement group_id="O2" value="3.00" lower_limit="-3.00" upper_limit="11.00"/>
                    <measurement group_id="O3" value="-2.00" lower_limit="-9.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pancreatic Enzymes at Baseline, 52 Weeks, and 4 Weeks After Last Dose</title>
        <description>Amylase (total and pancreas-derived [PD]) and lipase concentrations were measured at baseline and at 4 weeks after last dose (ALD).</description>
        <time_frame>Baseline and 52 weeks and 4 weeks after last dose</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable pancreatic enzyme data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pancreatic Enzymes at Baseline, 52 Weeks, and 4 Weeks After Last Dose</title>
          <description>Amylase (total and pancreas-derived [PD]) and lipase concentrations were measured at baseline and at 4 weeks after last dose (ALD).</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable pancreatic enzyme data.</population>
          <units>units per liter (U/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Amylase (total), Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.21" spread="27.89"/>
                    <measurement group_id="O2" value="58.59" spread="23.19"/>
                    <measurement group_id="O3" value="61.18" spread="26.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase (total), 52 weeks (n=284, 283, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.08" spread="30.29"/>
                    <measurement group_id="O2" value="60.97" spread="25.78"/>
                    <measurement group_id="O3" value="61.93" spread="27.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase (total), 4 weeks ALD (n=251, 259, 251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.69" spread="28.06"/>
                    <measurement group_id="O2" value="59.21" spread="30.32"/>
                    <measurement group_id="O3" value="62.13" spread="26.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase (PD), Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.56" spread="14.51"/>
                    <measurement group_id="O2" value="25.10" spread="13.48"/>
                    <measurement group_id="O3" value="26.43" spread="15.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase (PD), 52 weeks (n=284, 283, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.38" spread="18.15"/>
                    <measurement group_id="O2" value="27.86" spread="17.14"/>
                    <measurement group_id="O3" value="26.91" spread="17.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase (PD), 4 weeks ALD (n=251, 260, 251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.50" spread="15.49"/>
                    <measurement group_id="O2" value="25.77" spread="13.78"/>
                    <measurement group_id="O3" value="26.84" spread="15.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.42" spread="34.19"/>
                    <measurement group_id="O2" value="41.08" spread="32.80"/>
                    <measurement group_id="O3" value="43.20" spread="37.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase, 52 weeks (n=284, 283, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.57" spread="35.65"/>
                    <measurement group_id="O2" value="45.34" spread="31.23"/>
                    <measurement group_id="O3" value="39.39" spread="27.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase, 4 weeks ALD (n=252, 260, 251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.19" spread="36.92"/>
                    <measurement group_id="O2" value="41.86" spread="25.22"/>
                    <measurement group_id="O3" value="43.02" spread="35.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 26 and 52 Weeks in Serum Calcitonin</title>
        <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable serum calcitonin data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 26 and 52 Weeks in Serum Calcitonin</title>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable serum calcitonin data. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing</population>
          <units>picogram per milliliter (pcg/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 weeks (n=283, 282, 285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks (n=283, 283, 285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Calcitonin at Baseline, 52 Weeks, and 4 Weeks After Last Dose</title>
        <time_frame>Baseline and 52 weeks and 4 weeks after last dose</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable serum calcitonin data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Calcitonin at Baseline, 52 Weeks, and 4 Weeks After Last Dose</title>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable serum calcitonin data.</population>
          <units>picomole per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.78"/>
                    <measurement group_id="O2" value="0.73" spread="0.77"/>
                    <measurement group_id="O3" value="0.78" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks (n=284, 283, 285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.89"/>
                    <measurement group_id="O2" value="0.78" spread="0.90"/>
                    <measurement group_id="O3" value="0.80" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks after last dose (n=245, 254, 246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.87"/>
                    <measurement group_id="O2" value="0.73" spread="0.72"/>
                    <measurement group_id="O3" value="0.87" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 26 and 52 Weeks in Blood Pressure</title>
        <description>Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline blood pressure as a covariate.</description>
        <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable blood pressure data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 26 and 52 Weeks in Blood Pressure</title>
          <description>Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline blood pressure as a covariate.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable blood pressure data.</population>
          <units>milliliters of mercury (mmHg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, 26 weeks (n=255, 261, 258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" spread="0.88"/>
                    <measurement group_id="O2" value="-0.65" spread="0.87"/>
                    <measurement group_id="O3" value="2.23" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 52 weeks (n=239, 240, 246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.94"/>
                    <measurement group_id="O2" value="1.04" spread="0.93"/>
                    <measurement group_id="O3" value="1.98" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 26 weeks (n=255, 261, 258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.56"/>
                    <measurement group_id="O2" value="-0.08" spread="0.56"/>
                    <measurement group_id="O3" value="-0.23" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 52 weeks (n=239, 240, 246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.57"/>
                    <measurement group_id="O2" value="0.15" spread="0.57"/>
                    <measurement group_id="O3" value="-0.34" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure at Baseline, 52 Weeks, and 4 Weeks After Last Dose</title>
        <description>Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured.</description>
        <time_frame>Baseline and 52 weeks and 4 weeks after last dose</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable blood pressure data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure at Baseline, 52 Weeks, and 4 Weeks After Last Dose</title>
          <description>Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable blood pressure data.</population>
          <units>milliliters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.26" spread="16.56"/>
                    <measurement group_id="O2" value="134.03" spread="15.87"/>
                    <measurement group_id="O3" value="133.26" spread="16.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 52 weeks (n=290, 290, 295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.67" spread="15.40"/>
                    <measurement group_id="O2" value="134.31" spread="16.41"/>
                    <measurement group_id="O3" value="134.90" spread="16.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 4 weeks after last dose (n=260, 260, 255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.77" spread="16.80"/>
                    <measurement group_id="O2" value="134.72" spread="16.50"/>
                    <measurement group_id="O3" value="132.75" spread="16.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.33" spread="9.73"/>
                    <measurement group_id="O2" value="77.57" spread="9.00"/>
                    <measurement group_id="O3" value="77.18" spread="10.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 52 weeks (n=290, 290, 295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.33" spread="9.63"/>
                    <measurement group_id="O2" value="77.59" spread="9.74"/>
                    <measurement group_id="O3" value="77.07" spread="9.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 4 weeks after last dose (n=260, 260, 255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.58" spread="10.06"/>
                    <measurement group_id="O2" value="77.04" spread="9.60"/>
                    <measurement group_id="O3" value="76.94" spread="9.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 26 and 52 Weeks in Pulse Rate</title>
        <description>Seated pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline as a covariate</description>
        <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable seated pulse rate data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 26 and 52 Weeks in Pulse Rate</title>
          <description>Seated pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline as a covariate</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable seated pulse rate data.</population>
          <units>beats per minute (bpm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 weeks (n=255, 261, 258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" spread="0.57"/>
                    <measurement group_id="O2" value="2.79" spread="0.56"/>
                    <measurement group_id="O3" value="0.90" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks (n=239, 240, 246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="0.57"/>
                    <measurement group_id="O2" value="2.27" spread="0.57"/>
                    <measurement group_id="O3" value="0.93" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse Rate at Baseline, 52 Weeks, and 4 Weeks After Last Dose</title>
        <description>Seated pulse rate was measured.</description>
        <time_frame>Baseline and 52 weeks and 4 weeks after last dose</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable seated pulse rate data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse Rate at Baseline, 52 Weeks, and 4 Weeks After Last Dose</title>
          <description>Seated pulse rate was measured.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable seated pulse rate data.</population>
          <units>beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.26" spread="11.03"/>
                    <measurement group_id="O2" value="75.08" spread="11.10"/>
                    <measurement group_id="O3" value="74.54" spread="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks (n=290, 290, 295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.30" spread="11.01"/>
                    <measurement group_id="O2" value="77.83" spread="10.90"/>
                    <measurement group_id="O3" value="76.02" spread="11.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks after last dose (n=260, 260, 255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.52" spread="11.09"/>
                    <measurement group_id="O2" value="74.99" spread="11.98"/>
                    <measurement group_id="O3" value="75.27" spread="11.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval</title>
        <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline value as a covariate.</description>
        <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable ECG QTcF or PR Interval data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval</title>
          <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline value as a covariate.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable ECG QTcF or PR Interval data.</population>
          <units>milliseconds (msec)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QTcF interval, 26 weeks (n=241, 242, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="1.13"/>
                    <measurement group_id="O2" value="0.30" spread="1.12"/>
                    <measurement group_id="O3" value="1.59" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval, 52 weeks (n= 222, 221, 221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="1.13"/>
                    <measurement group_id="O2" value="1.48" spread="1.13"/>
                    <measurement group_id="O3" value="1.80" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval, 26 weeks (n=238, 243, 236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.95"/>
                    <measurement group_id="O2" value="-1.75" spread="0.94"/>
                    <measurement group_id="O3" value="-1.13" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval, 52 weeks (n=220, 222, 221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="1.00"/>
                    <measurement group_id="O2" value="0.05" spread="0.99"/>
                    <measurement group_id="O3" value="-0.43" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Heart Rate</title>
        <description>Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline value as a covariate.</description>
        <time_frame>Baseline, 26 weeks, and 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable ECG heart rate data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Heart Rate</title>
          <description>Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline value as a covariate.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine with evaluable ECG heart rate data.</population>
          <units>beats per minute (bpm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 weeks (n=244, 246, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.95" spread="0.65"/>
                    <measurement group_id="O2" value="4.18" spread="0.65"/>
                    <measurement group_id="O3" value="1.37" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks (n=230, 226, 230)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" spread="0.67"/>
                    <measurement group_id="O2" value="3.83" spread="0.67"/>
                    <measurement group_id="O3" value="1.03" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events of Adjudicated Pancreatitis up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose</title>
        <description>The number of adjudicated (by an independent Clinical Endpoint Committee [CEC]) pancreatic events is summarized at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of Adjudicated Pancreatitis up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose</title>
          <description>The number of adjudicated (by an independent Clinical Endpoint Committee [CEC]) pancreatic events is summarized at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data from 26 weeks was not analyzed for this outcome.</measurement>
                    <measurement group_id="O2" value="NA">Data from 26 weeks was not analyzed for this outcome.</measurement>
                    <measurement group_id="O3" value="NA">Data from 26 weeks was not analyzed for this outcome.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks after last dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data from 4 weeks after last dose was not analyzed for this outcome.</measurement>
                    <measurement group_id="O2" value="NA">Data from 4 weeks after last dose was not analyzed for this outcome.</measurement>
                    <measurement group_id="O3" value="NA">Data from 4 weeks after last dose was not analyzed for this outcome.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Self-reported Hypoglycemic Events up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose</title>
        <description>Hypoglycemic events (HE) were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions and had a plasma glucose [PG] of ≤ 70 milligrams per deciliter [mg/dL]), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a PG of ≤ 70 mg/dL), or asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL). The number of participants with self-reported hypoglycemic events is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through 26 weeks and 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine. Only pre-rescue measurements were used.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Self-reported Hypoglycemic Events up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose</title>
          <description>Hypoglycemic events (HE) were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions and had a plasma glucose [PG] of ≤ 70 milligrams per deciliter [mg/dL]), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a PG of ≤ 70 mg/dL), or asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL). The number of participants with self-reported hypoglycemic events is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine. Only pre-rescue measurements were used.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severe HE, 26 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe HE, 52 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe HE, 4 weeks after last dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data from 4 weeks after last dose was not analyzed for this outcome.</measurement>
                    <measurement group_id="O2" value="NA">Data from 4 weeks after last dose was not analyzed for this outcome.</measurement>
                    <measurement group_id="O3" value="NA">Data from 4 weeks after last dose was not analyzed for this outcome.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented Symptomatic HE, 26 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                    <measurement group_id="O2" value="242"/>
                    <measurement group_id="O3" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented Symptomatic HE, 52 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235"/>
                    <measurement group_id="O2" value="250"/>
                    <measurement group_id="O3" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented Symptomatic HE, 4 weeks after last dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data from 4 weeks after last dose was not analyzed for this outcome.</measurement>
                    <measurement group_id="O2" value="NA">Data from 4 weeks after last dose was not analyzed for this outcome.</measurement>
                    <measurement group_id="O3" value="NA">Data from 4 weeks after last dose was not analyzed for this outcome.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymptomatic HE, 26 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="179"/>
                    <measurement group_id="O3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymptomatic HE, 52 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                    <measurement group_id="O2" value="196"/>
                    <measurement group_id="O3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymptomatic HE, 4 weeks after last dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data from 4 weeks after last dose was not analyzed for this outcome.</measurement>
                    <measurement group_id="O2" value="NA">Data from 4 weeks after last dose was not analyzed for this outcome.</measurement>
                    <measurement group_id="O3" value="NA">Data from 4 weeks after last dose was not analyzed for this outcome.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total HE, 26 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250"/>
                    <measurement group_id="O2" value="258"/>
                    <measurement group_id="O3" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total HE, 52 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252"/>
                    <measurement group_id="O2" value="263"/>
                    <measurement group_id="O3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total HE, 4 weeks after last dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data from 4 weeks after last dose was not analyzed for this outcome.</measurement>
                    <measurement group_id="O2" value="NA">Data from 4 weeks after last dose was not analyzed for this outcome.</measurement>
                    <measurement group_id="O3" value="NA">Data from 4 weeks after last dose was not analyzed for this outcome.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Self-reported Hypoglycemic Events up to 52 Weeks</title>
        <description>Hypoglycemic events (HE) were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions and had a plasma glucose [PG] of ≤ 70 milligrams per deciliter [mg/dL]), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a PG of ≤ 70 mg/dL), or asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine. Only pre-rescue measurements were used.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Self-reported Hypoglycemic Events up to 52 Weeks</title>
          <description>Hypoglycemic events (HE) were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions and had a plasma glucose [PG] of ≤ 70 milligrams per deciliter [mg/dL]), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a PG of ≤ 70 mg/dL), or asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine. Only pre-rescue measurements were used.</population>
          <units>events per participant per year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severe HE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.19"/>
                    <measurement group_id="O2" value="0.05" spread="0.50"/>
                    <measurement group_id="O3" value="0.08" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented Symptomatic HE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.98" spread="39.64"/>
                    <measurement group_id="O2" value="35.03" spread="44.94"/>
                    <measurement group_id="O3" value="39.90" spread="50.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymptomatic HE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.55" spread="19.52"/>
                    <measurement group_id="O2" value="11.56" spread="24.69"/>
                    <measurement group_id="O3" value="14.20" spread="23.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total HE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.52" spread="46.51"/>
                    <measurement group_id="O2" value="47.42" spread="54.39"/>
                    <measurement group_id="O3" value="55.93" spread="59.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adjudicated Cardiovascular Events up to 52 Weeks</title>
        <description>Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through 52 weeks</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adjudicated Cardiovascular Events up to 52 Weeks</title>
          <description>Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any cardiovascular event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fatal cardiovascular event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any non-fatal cardiovascular event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent LY2189265 Antibodies up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose</title>
        <description>A participant was considered to have treatment emergent LY2189265 anti-drug antibodies (ADA) if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.</description>
        <time_frame>Baseline through 4 weeks after last dose</time_frame>
        <population>Participants who received at least one dose of LY2189265 with evaluable LY2189265 ADA data.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg or 0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg) or 0.75 mg , subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent LY2189265 Antibodies up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose</title>
          <description>A participant was considered to have treatment emergent LY2189265 anti-drug antibodies (ADA) if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.</description>
          <population>Participants who received at least one dose of LY2189265 with evaluable LY2189265 ADA data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data from 26 weeks was not analyzed for this outcome.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data from 52 weeks was not analyzed for this outcome.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks after last dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose</title>
        <description>A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 weeks, 52 weeks, and 4 weeks after last dose. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through 26 weeks, 52 weeks, and 4 weeks after last dose</time_frame>
        <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine</title>
            <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose</title>
          <description>A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 weeks, 52 weeks, and 4 weeks after last dose. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
          <population>Participants who were randomized and received at least one dose of LY2189265 or Insulin Glargine.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                    <measurement group_id="O2" value="216"/>
                    <measurement group_id="O3" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="230"/>
                    <measurement group_id="O3" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks after last dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="235"/>
                    <measurement group_id="O3" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1.5 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
        </group>
        <group group_id="E2">
          <title>0.75 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
        </group>
        <group group_id="E3">
          <title>Insulin Glargine</title>
          <description>Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Hemorrhagic anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Iron deficiency anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Atrioventricular block third degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Cardiac pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <description>Event resulted in death</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Coronary atherosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Coronary insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Decompensated heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Fibrillation ventricular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Heart block third degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Infarct myocardial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Non st segment elevation myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Non stemi</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Non-sustained ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Unstable angina</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <description>Event resulted in death</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Retinal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Abdominal herniation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Chronic diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Gastroenteritis noninfectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Hemorrhoidal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Paralytic ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Chest pain exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Generalized edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Multiple organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Ancylostomiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Cellulitis of foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Cellulitis of leg</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Gangrenous appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Hookworm infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Infected toe</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Pleurisy viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>One event resulted in one death in 0.75 mg LY2189265 arm</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>One event resulted in one death in 1.5 mg LY2189265 arm</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Staphylococcus aureus septicemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Supraglottitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Urinary infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Falling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Fractured ribs</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Fractured sternum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Knee fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Leg injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture l1</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Meniscus tear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Quadriceps tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Suture related complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Torn muscle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="295"/>
                <counts group_id="E2" events="17" subjects_affected="8" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="295"/>
                <counts group_id="E2" events="16" subjects_affected="7" subjects_at_risk="293"/>
                <counts group_id="E3" events="20" subjects_affected="12" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Hypoglycemic episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Cervical pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Lumbar pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Muscle atrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Osteoarthritis aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Rotator cuff tear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Gallbladder adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Rectal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Hemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Hypoglycemic coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Ischemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Lumboischialgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Orthostatic collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Palsy bells</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Transient cerebral ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Unilateral carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Viith nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Mental confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Renal stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Unilateral renal artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Ureteral calculus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Ureteric calculus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Premenopausal menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Atherosclerosis generalized</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="219" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="232" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="203" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="295"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="295"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="293"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="62" subjects_affected="44" subjects_at_risk="295"/>
                <counts group_id="E2" events="67" subjects_affected="34" subjects_at_risk="293"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="295"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="293"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="295"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="115" subjects_affected="76" subjects_at_risk="295"/>
                <counts group_id="E2" events="74" subjects_affected="52" subjects_at_risk="293"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="46" subjects_affected="35" subjects_at_risk="295"/>
                <counts group_id="E2" events="49" subjects_affected="31" subjects_at_risk="293"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="295"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="293"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="295"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="293"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="295"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="293"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Common cold</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="295"/>
                <counts group_id="E2" events="37" subjects_affected="28" subjects_at_risk="293"/>
                <counts group_id="E3" events="33" subjects_affected="26" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Flu syndrome</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="295"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="293"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="43" subjects_affected="33" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="295"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="295"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="293"/>
                <counts group_id="E3" events="18" subjects_affected="11" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="295"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="295"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="295"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="293"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Dyslipidemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="295"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="293"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="293"/>
                <counts group_id="E3" events="21" subjects_affected="16" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="295"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="293"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="295"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="293"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="295"/>
                <counts group_id="E2" events="27" subjects_affected="20" subjects_at_risk="293"/>
                <counts group_id="E3" events="20" subjects_affected="17" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="295"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="293"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

